Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(11%)
Results Posted
0%(0 trials)
Terminated
1(11%)

Phase Distribution

Ph not_applicable
1
11%
Ph phase_1
2
22%
Ph phase_2
3
33%
Ph phase_4
2
22%
Ph phase_3
1
11%

Phase Distribution

2

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
2(22.2%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
Terminated1
Recruiting1
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (22.2%)
Phase 23 (33.3%)
Phase 31 (11.1%)
Phase 42 (22.2%)
N/A1 (11.1%)

Trials by Status

terminated111%
recruiting111%
not_yet_recruiting111%
completed556%
unknown111%

Recent Activity

1 active trials
Showing 5 of 9
recruitingnot_applicable

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

NCT06276010
completedphase_1

DEFINE - Evaluating Therapies for COVID-19

NCT04473053
completedphase_1

Oral Nafamostat in Healthy Volunteers (NAF-101)

NCT04406415
terminatedphase_3

Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal

NCT04390594
unknownphase_2

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)

NCT04352400
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06276010Not Applicable

Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

Recruiting
NCT04473053Phase 1

DEFINE - Evaluating Therapies for COVID-19

Completed
NCT04406415Phase 1

Oral Nafamostat in Healthy Volunteers (NAF-101)

Completed
NCT04390594Phase 3

Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal

Terminated
NCT04352400Phase 2

Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)

Unknown
NCT06078839Phase 4

Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy

Not Yet Recruiting
NCT04628143Phase 2

A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

Completed
NCT04623021Phase 2

A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

Completed
NCT02478242Phase 4

Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9